Neovacs Finishes Enrolling Patients in Trial Testing Potential SLE Vaccine

French pharmaceutical firm Neovacs has completed enrollment for a Phase 2b clinical trial (IFN-K-002) to evaluate the efficacy and safety of IFNα-Kinoid to treat systemic lupus erythematosus (SLE). “The completion of enrollment is an important milestone for our IFN Kinoid program and confirms the interest of leading clinicians conducting our trial in this novel…

Neovacs Ready to Launch IFN-K-002 Clinical Trial for Systemic Lupus Erythematosus After Receiving First Batch of EU Approvals

NEOVACS, a leading biotechnology company focused on an active immunotherapy technology platform (Kinoids) with applications in autoimmune and/or inflammatory diseases, announced it has been granted initial approvals by regulatory agencies and ethics committees in several countries in the European Union for a Phase IIb clinical study of investigational IFNα-Kinoid for patients…